Protagonist Therapeutics Inc expected to post a loss of 65 cents a share - Earnings Preview

Protagonist Therapeutics

31/07/2023 14:42

* Protagonist Therapeutics Inc  PTGX.OQ   PTGX.O  is
expected
to show a fall in quarterly revenue when it reports  results on
August 2 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Protagonist
Therapeutics
Inc is for a loss of 65 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $38​, above​ its last closing price
of $19.09. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.77       -0.73      -0.67     Beat    7.8
 Dec. 31 2023  -0.52       -0.64      -0.69     Missed  -8.1
 Sep. 30 2022  -0.86       -0.87      -0.64     Beat    26.3​
 Jun. 30 2022  -0.91       -0.93      -0.84     Beat    9.4
 ​​Mar.        -0.58       -0.63      -0.43     Beat    31.6
 31 2022                                                
 Dec. 31 2021  -0.81       -0.78      -0.77     Beat    1.6​
 Sep. 30 2021  -0.69       -0.67      -0.70     Missed  -4.5
 Jun. 30 2021  -0.54       -0.55      -0.69     Missed  -26.1
 This summary was machine generated July 31 at 13:42 GMT.  All
figures in US dollars  unless otherwise stated